DE69833388D1 - Dna impfstoffe gegen zecken-flavivieren - Google Patents

Dna impfstoffe gegen zecken-flavivieren

Info

Publication number
DE69833388D1
DE69833388D1 DE69833388T DE69833388T DE69833388D1 DE 69833388 D1 DE69833388 D1 DE 69833388D1 DE 69833388 T DE69833388 T DE 69833388T DE 69833388 T DE69833388 T DE 69833388T DE 69833388 D1 DE69833388 D1 DE 69833388D1
Authority
DE
Germany
Prior art keywords
flavors
dna vaccines
vaccines against
against tile
tile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69833388T
Other languages
English (en)
Inventor
S Schmaljohn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Army Medical Research and Materiel Command USAMRMC
Original Assignee
US Army Medical Research and Materiel Command USAMRMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Army Medical Research and Materiel Command USAMRMC filed Critical US Army Medical Research and Materiel Command USAMRMC
Application granted granted Critical
Publication of DE69833388D1 publication Critical patent/DE69833388D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69833388T 1997-11-20 1998-11-20 Dna impfstoffe gegen zecken-flavivieren Expired - Lifetime DE69833388D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6575097P 1997-11-20 1997-11-20
PCT/US1998/025322 WO1999026653A1 (en) 1997-11-20 1998-11-20 Dna vaccines against tick-borne flaviviruses

Publications (1)

Publication Number Publication Date
DE69833388D1 true DE69833388D1 (de) 2006-04-13

Family

ID=22064858

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69833388T Expired - Lifetime DE69833388D1 (de) 1997-11-20 1998-11-20 Dna impfstoffe gegen zecken-flavivieren

Country Status (5)

Country Link
US (1) US6258788B1 (de)
EP (1) EP1047448B1 (de)
AT (1) ATE316796T1 (de)
DE (1) DE69833388D1 (de)
WO (1) WO1999026653A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
IL139844A0 (en) 1998-06-04 2002-02-10 Us Gov Health & Human Serv Nucleic acid vaccines for prevention of flavivirus infection
EP1228237A1 (de) * 1999-11-01 2002-08-07 Chiron Corporation Expressionsvektoren, transfektionssysteme, und verfahren zur verwendung
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
AU2003263853A1 (en) * 2002-08-16 2004-03-03 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens
WO2006067122A2 (en) 2004-12-20 2006-06-29 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
WO2006120230A2 (en) 2005-05-12 2006-11-16 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP1893645A1 (de) * 2005-06-23 2008-03-05 Crucell Holland B.V. Optimierung von antikörpern gegen das west-nile-virus
KR101508390B1 (ko) 2006-06-06 2015-04-08 크루셀 홀란드 비.브이. 포도상구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5506125A (en) 1993-12-22 1996-04-09 Agracetus, Inc. Gene delivery instrument with replaceable cartridges
NZ279995A (en) 1994-01-21 1998-04-27 Powderject Vaccines Inc Gas driven gene delivery instrument with a conical exit nozzle and a cartridge with an arcuate, linear passage
HU224199B1 (hu) 1994-07-08 2005-06-28 Baxter Aktiengesellschaft Flavivírus-fertőzések elleni immunizálásra alkalmas, csupasz nukleinsavat tartalmazó vakcina

Also Published As

Publication number Publication date
WO1999026653A1 (en) 1999-06-03
EP1047448B1 (de) 2006-02-01
ATE316796T1 (de) 2006-02-15
EP1047448A1 (de) 2000-11-02
US6258788B1 (en) 2001-07-10

Similar Documents

Publication Publication Date Title
IL168584A (en) West nile virus vaccine
EP1552298A4 (de) Rekombinante gewebeschützende cytokine und dafür codierende nukleinsäuren zum schutz, zur wiederherstellung und zur verbesserung darauf ansprechender zellen, gewebe und organe
IL219528A0 (en) Vaccine comprising recombinant modified vaccine ankara virus and uses thereof
DE69833388D1 (de) Dna impfstoffe gegen zecken-flavivieren
AU9092601A (en) Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof
EP1554301A4 (de) Tetravalente dengue-vakzine mit einer blichen 30 nucleotid-deletion in 3'-utr von dengue-typen 1,2,3 und 4, oder antigene chimäre dengue-viren 1,2,3 und 4
WO2001051083A3 (en) Innate immunity-stimulating compositions of cpg and saponin and methods thereof
WO2002062296A3 (en) Methods and compositions useful for stimulating an immune response
AU2001241918A1 (en) Methods of enhancing activity of vaccines and vaccine compositions
EP1552016A4 (de) Verfahren zur impfstoffidentifizierung sowie nukleinsäure- und/oder polypeptidsequenzen der herpesvirus-familie umfassende zusammensetzungen zur impfung
HK1076835A1 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
GB2382076B (en) Protected aminofuntionalized polymerization initiators and methods of making and using same
AU2001273559A1 (en) Methods of ligation mediated chimeragenesis utilizing populations of scaffold and donor nucleic acids
EP1687033A4 (de) Verbesserung der impfstoff-induzierten immunreaktionen und schutz durch heterologe verstärkung mit alphavirus replicon vakzine
AU2003304145A1 (en) Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus borrelia
IL174325A0 (en) Dna vaccine compositions and methods of use
IL144845A0 (en) Vaccines and gene therapy compositions and methods of making and using the same
SG169325A1 (en) Promoters for expression in modified vaccinia virus ankara
EP1651258A4 (de) Hepatitis virus kern-proteine als vakzine-plattformen und anwendungsverfahren dafür
AU2002367753A1 (en) Ehrlichia canis genes and vaccines
DE60131975D1 (de) Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
AU2002347464A1 (en) Anti-arthropod vector vaccines methods of selecting and uses thereof
AU2002245039A1 (en) Genetic typing of human genes and related materials and methods
AU2002362767A1 (en) Recombinant rabies vaccine and methods of preparation and use
AUPR020900A0 (en) Vaccines and methods of vaccination

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: UNITED STATES ARMY MEDICAL RESEARCH AND MATERIEL C

8332 No legal effect for de